Sign In
Buy CRSP
$46.99
-0.790 (-1.65%)
At Close: Jul 20, 2026
CRISPR Therapeutics AG (CRSP) Morgan Stanley 20th Annual Global Healthcare Conference (Transcript)
05:59pm, Monday, 12'th Sep 2022
CRISPR Therapeutics AG (NASDAQ:CRSP ) Morgan Stanley 20th Annual Global Healthcare Conference Call September 12, 2022 11:40 AM ET Company Participants Samarth Kulkarni - Chief Executive Officer Confer
Crispr Therapeutics: Nearing Harvest Season
02:19pm, Thursday, 08'th Sep 2022
Crispr Therapeutics is continuing to show strong execution. An announcement of the information release of discussions surrounding the CTX001 filing is expected in weeks.
CRISPR Therapeutics AG (CRSP) Citi 17th Annual BioPharma Conference Transcript
02:29pm, Wednesday, 07'th Sep 2022
CRISPR Therapeutics AG (NASDAQ:CRSP ) Citi 17th Annual BioPharma Conference September 7, 2022 8:50 AM ET Company Participants Sam Kulkarni – Chief Executive Officer Conference Call Participants Yiga
CRISPR Therapeutics' (CRSP) Pipeline Development Fuels Growth
12:02pm, Tuesday, 06'th Sep 2022
While CRISPR Therapeutics' (CRSP) lead candidate is still a couple of years away from commercialization, it is highly dependent on collaboration revenues to fund its ongoing pipeline.
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
03:26pm, Wednesday, 31'st Aug 2022
The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
08:00am, Wednesday, 31'st Aug 2022
ZUG, Switzerland and CAMBRIDGE, Mass., Aug. 31, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ser
3 Biotech Stocks You Can Buy and Hold for the Next Decade
02:23pm, Monday, 29'th Aug 2022 The Motley Fool
All three companies are attempting to use unique discoveries to make marketable therapies.
3 Growth Stocks Poised to Skyrocket
10:08am, Saturday, 27'th Aug 2022 The Motley Fool
All of them could have huge catalysts on the way.
7 Cathie Wood Stocks to Buy on the Dip
02:00pm, Monday, 22'nd Aug 2022
Cathie Wood is well-known in the investment world as the face of ARK Invest, the firm she founded in 2014. ARK itself stands for Active Research Knowledge.
5 Cathie Wood Stocks Signaling “The Bear Market Is Over”
01:34pm, Monday, 22'nd Aug 2022
This article is excerpted from Tom Yeung's Profit & Protection newsletter dated Aug. 16, 2022. To make sure you don't miss any of Tom's picks, subscribe to his mailing list here.
Vertex (VRTX) Stock Up 36% This Year So Far: What Lies Ahead?
01:04pm, Monday, 22'nd Aug 2022 Zacks Investment Research
Vertex's (VRTX) CF sales rise 22% in the first half of 2022, primarily driven by higher sales of Trikafta. Programs in five disease areas are now entering or progressing through late-stage clinical de
3 Monster Stocks in the Making to Buy Right Now
10:10am, Saturday, 20'th Aug 2022 The Motley Fool
These stocks have the potential to be huge winners for investors over the long term.
3 Monster Stocks in the Making to Buy Right Now
06:10am, Saturday, 20'th Aug 2022
These stocks have the potential to be huge winners for investors over the long term.
Why This Analyst Sees A 51% Return On This Cathie Wood-Favored Biotech Stock
10:33pm, Wednesday, 17'th Aug 2022 Benzinga
Biotech stocks have the potential for huge gains if a product or drug is deemed effective and safe, but investing in the shares of those companies can be volatile.
Cathie Wood and her flagship ARK Inn
A Comprehensive Guide to Genomic ETFs
12:03pm, Friday, 12'th Aug 2022
Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.
